Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.51 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421485 | 0.92 | HSD11B1 (0.61) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL422227 | 0.88 | CES2 (0.44) | HSD11B1HSD11B2CES2CES1MEN1 | |
| SCHEMBL422918 | 0.88 | HSD11B2 (0.43) | HSD11B1HSD11B2CES2CES1MEN1 | |
| SCHEMBL421035 | 0.87 | HSD11B1 (0.45) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL419871 | 0.86 | HSD11B1 (0.51) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL418097 | 0.85 | HSD11B1 (0.60) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL419086 | 0.85 | HSD11B1 (0.47) | HSD11B1HSD11B2 | |
| SCHEMBL17268560 | 0.84 | HSD11B1 (0.47) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL20130320 | 0.79 | HSD11B1 (0.42) | HSD11B1HSD11B2CES2CES1HSD17B1 | |
| SCHEMBL422802 | 0.78 | HSD11B2 (0.45) | HSD11B1HSD11B2CES2CES1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476315-B2 | N-hydroxy C29-amide derivatives of oleandrane | ONEPHARM RESEARCH & DEVELOPMENT GMBH (AT) | 2013-07-02 | — | — | US | disclosed |
| US-20120022154-A1 | N-HYDROXY C29-AMIDE DERIVATIVES OF OLEANDRANE | ONEPHARM RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-26 | — | — | US | disclosed |
| EP-2228380-A1 | Novel triterpene derivatives | onepharm Research & Development GmbH (AT) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022154-A1 | N-HYDROXY C29-AMIDE DERIVATIVES OF OLEANDRANE | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885CES2 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.